Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | AGXT | P21549 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13378245 | 0.91 | APLNR (0.33) | APLNRIDO1AGXT | |
| SCHEMBL13378221 | 0.91 | APLNR (0.33) | APLNRIDO1AGXT | |
| SCHEMBL14253541 | 0.89 | — | — | |
| SCHEMBL14533017 | 0.89 | IDO1 (0.33) | APLNRIDO1AGXTALDH1A1CYP3A4 | |
| SCHEMBL7526812 | 0.88 | APLNR (0.35) | APLNRIDO1AGXT | |
| SCHEMBL5814009 | 0.87 | APLNR (0.35) | APLNRIDO1AGXTALDH1A1CYP3A4 | |
| SCHEMBL5813999 | 0.87 | APLNR (0.35) | APLNRIDO1AGXTALDH1A1CYP3A4 | |
| SCHEMBL14253511 | 0.85 | — | — | |
| SCHEMBL5819466 | 0.85 | SMN1; SMN2 (0.38) | IDO1AGXTALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL5819472 | 0.85 | SMN1; SMN2 (0.38) | IDO1AGXTALDH1A1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700783-B2 | Synthesis of discodermolide and variants thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-04-20 | — | — | US | disclosed |
| US-20070276144-A1 | Synthesis Of Discodermolide And Variants Thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2007-11-29 | — | — | US | disclosed |
| US-20040018598-A1 | Bio-intermediates for use in the chemical synthesis of polyketides | SANTI DANIEL (US) | 2004-01-29 | — | — | US | disclosed |
| US-20020052028-A1 | Bio-intermediates for use in the chemical synthesis of polyketides | KOSAN BIOSCIENCES, INC. | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276144-A1 | Synthesis Of Discodermolide And Variants Thereof | EML4, CYP17A1, CYP21A2 | APLNR 3047/4885IDO1 4182/4885AGXT 1059/4885 |
| US-20040018598-A1 | Bio-intermediates for use in the chemical synthesis of polyketides | DHPS, FDFT1, COASY | APLNR 2576/4885IDO1 3441/4885AGXT 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.